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equipment costs (depreciation of equipment); medication-error and complication
costs including bloodstream-infection (BSI) costs. Total costs were calculated per
bag for neonates and infants. Data and resources utilized were derived from three
Belgian hospitals. Medication-error and BSI costs were derived via literature. A
bottom-up approach was used to assess total costs by assigning monetary values to
the resource-utilization using published list prices, literature and interview data.
RESULTS: The daily total cost of one compounded PN bag for neonates equaled
90.19€. Overall, labor costs accounted for 42% of total costs and represented the
highest proportion, followed by costs due to medication-error and incremental BSI
costs (22%). Disposables accounted for 22% and nutrients for 12%. Average costs per
bag for infants 2yr were 108.37€, with labor costs also representing the highest
proportion (35%). Nutrients represented 27% of total costs, while medication-error
and incremental BSI costs accounted for 19% and disposables for 18%.
CONCLUSIONS: This is the first time that complete costs of PN have been considered,
including consequential costs of medication-error and BSI costs. The data showed that a
significant proportion of the total costs of PN is due to these costs as well as labor costs.
Ready prepared PN could reduce staff-time, error and infection rates.
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OBJECTIVES: Syncope represents about 2% of Emergency Room (ER) admissions.
The European Society of Cardiology (ESC) published in 2009 Guidelines for the
diagnosis/management of syncope. Several studies have tried to investigate Guide-
lines adoption and clinical pathways for syncope care. The first objective of PROSIT
was to relate syncope management in Italian hospitals, including clinical out-
comes and costs. METHODS: This is a retrospective, longitudinal (6 months), mul-
ticenter study, considering every patients (pts) admitted in ER with the diagnosis of
syncope. Data about ER, laboratory tests, hospitalizations, final diagnosis and re-
lated costs from the Regional Health Service (RHS) were considered since the ER
admission till the hospital discharge RESULTS: A total of 1,632 pts (mean age: 61;
SD23 ) were recruited in 9 Italian hospitals. A mean of 4.5 laboratory tests per
patient during ER stay were performed; unfortunately many pts did not undergo
specific tests for syncope (e.g. ECG monitoring and carotid sinus massage) recom-
mended by ESC guidelines. 40,3% of pts without definitive diagnosis were hospi-
talized in ER department. The mean cost of ER tests and ER hospitalizations was
174.09€ per patient. 28% of pts was admitted in different hospital departments
(after first ER evaluation), with mean stay of 9 days (SD6). The cost sustained was
571.39 € per patient. The 35% of patients with syncope remained undiagnosed after
ER or hospitalization discharge, with 26% of total costs sustained for these patients.
CONCLUSIONS: Different approaches to achieve syncope diagnosis were founded
in PROSIT study. The diagnosis of syncope has a clinical and significant impact on
costs. Hospitalizations, for which the majority of costs are sustained, help to find a
diagnosis but a greater adherence to guidelines could reduce undiagnosed syn-
cope, actually still elevated, and related costs due to diagnostics and inappropriate
admissions.
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OBJECTIVES: Achieving optimal patient adherence to IV medication is a major
challenge in clinical management of chronic diseases. The objectives of this liter-
ature review were to identify the factors that influence patient non-adherence to IV
medication for chronic conditions and evaluate if an optimum relationship be-
tween dosing frequency and adherence exists. METHODS: A database search for
adherence to IV medication was conducted through Medline, Embase and Biosis
databases. Inclusion and exclusion criteria were applied before each published
article or abstract (1990-May 2012) was appraised. Primary research studies, in
English language, with an analysis of adherence rates and or factors in a chronic
condition were included. RESULTS: Twelve primary studies were identified and
reviewed across two chronic conditions: osteoporosis (8) and Crohn’s Disease (4).
Multiple patient-related and therapy-related factors were reported to influence
non-adherence to IV medication. The most frequently identified factors influenc-
ing non-adherence were therapy-related: poor tolerability and side effects (3 stud-
ies) and inconvenience of location for therapy (3 studies). In two studies comparing
directly IV dosing frequency in osteoporosis therapy, adherence was greater for
annual therapy vs every 3 months (82% vs 58-62% and 65.6% vs 56.6% respectively).
There was a wide range in the reported rate of non-adherence across studies in
both osteoporosis and Crohn’s Disease (17.1% to 43.4% and 27% to 40%, respec-
tively). A threshold for IV dosing frequency that optimises adherence could not
clearly be assessed. CONCLUSIONS: Dosing frequency appears to be one determi-
nant of non-adherence among chronic diseases along with multiple other factors,
most notably tolerability and convenience. Further primary research is required to
determine the relative influence of IV dosing frequency and other therapy-related
factors in management of specific chronic diseases in clinical practice.
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OBJECTIVES: To determine the association between potentially inappropriate pre-
scribing (PIP) defined by STOPP (Screening Tool of Older Person’s PIP) and adverse
drug events (ADEs), health related quality of life (HRQOL) and hospitalisation in
older primary care patients. METHODS: A cross-sectional study of 904 patients
aged 70 years recruited from 15 general practices in Ireland in 2010. PIP was
defined by the STOPP criteria. ADEs defined as any injury resulting from drug
therapy, were measured by patient self-report for the previous 6 months and re-
viewed by two independent clinicians. HRQOL was measured by the EQ-5D and
utility values calculated based on UK population values. Hospitalisation was mea-
sured using patients’ medical records and self-report. Multilevel logistic, linear and
poisson regression was used to examine how ADEs, utility and hospitalisation
varied by PIP after adjusting for patient and practice level cofounding variables
including socioeconomic status, co-morbidity, number of different repeat drug
classes and adherence. Adherence was measured by the medication possession
ratio using patients’ national pharmacy claims data and self-report. RESULTS: The
overall prevalence of PIP was 42% (n377). Patients with 2 PIP indicators were
twice as likely to have an ADE (OR, 2.21; 95% CI, 1.02, 4.83, p0.05), had a signifi-
cantly lower mean HRQOL utility (coefficient, -0.11, SE 0.03, p0.001) and a 34%
increase in the expected rate of hospitalisation (IRR, 1.34; 95% CI, 1.15, 1.57,
p0.001) after adjustment. The number of repeat drug classes and adherence were
also significantly associated with ADEs, impaired HRQOL and increased
hospitalisation. CONCLUSIONS: PIP defined by the STOPP criteria was significantly
associated with patient reported ADEs, HRQOL and hospitalisation. There is limited
data regarding the association between PIP and adverse health outcomes in older
patients. Studies are important to facilitate the design of better interventions to
improve medication safety in older patients.
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OBJECTIVES: Medication non-adherence is associated with poorer health status;
yet, intentional (INA; e.g., purposefully skipping doses) and unintentional (UNA;
e.g., forgetting) non-adherence levels may differ across disease areas and associ-
ated therapies. This study investigated non-adherence across prevalent conditions
in a Russian patient population. METHODS: Russia 2011 National Health and Well-
ness Survey data included 2,285 (of 10,039) respondents who completed the
Morisky Medication Adherence Scale (MMAS) for the following treated conditions:
pain, arthritis, asthma, depression, diabetes, and hypertension. MMAS items were
summed to create INA (“stop taking medicine when feeling better” and “. . .when
feeling worse”) and UNA (“forget to take medicine” and “careless about taking
medicine”) scores: 0adherence to 2high non-adherence. Logistic regressions
predicted INA/UNA (1 vs. 0) from condition, gender, age, Charlson Comorbidity
Index score, BMI category, marital status, exercise 12 times monthly, and ciga-
rette smoking. RESULTS:Among patients reporting MMAS for pain (n719), arthri-
tis (n209), asthma (n87), depression (n177), diabetes (n87), and hypertension
(n1,006), 51.3% were male, mean age was 49.3 years (SD16.2), and 77.7% and
52.3% exhibited INA and UNA, respectively (rINA/UNA0.36, p0.001). Pain had the
highest INA rate (89.2%). Diabetes had the lowest non-adherence
(INAUNA44.8%). Asthma had low UNA (41.4%). Depression had the highest UNA
(66.6%) and second-highest INA (81.4%). Adjusting for covariates, respondents in
any condition vs. pain had lower relative odds of INA, from OR0.12 (diabetes) to
0.52 (depression), all p0.01; respondents with arthritis and depression vs. pain
had higher relative odds of UNA (OR1.45 and 1.74, respectively), both p0.05.
Covariates of INA were non-significant. Younger age, lack of exercise, male sex,
obesity, and recent divorce/separation/widowhood were associated with UNA, all
p0.05. CONCLUSIONS: High, varying levels of non-adherence were found across
prevalent conditions in Russia. Adherence may be improved by matching pharma-
cotherapy profiles to specific conditions (e.g., favorable tolerability for high-INA
conditions such as pain).
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OBJECTIVES: To measure the impact of periods on the lives of women reporting a
problem, through the use of health related quality of life instruments in a real-
world setting. METHODS: The evaluation was conducted throughout the UK using
the web-based PROBE system (patient reported outcomes based evaluation). As
women may not seek professional health care advice for this issue, recruitment
was tailored to identify a sample representative of all women with problem peri-
ods. An initial screening questionnaire was used to programme the timing of the
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